MX2018002237A - Nuevos biomarcadores y metodos para tratar el cancer. - Google Patents
Nuevos biomarcadores y metodos para tratar el cancer.Info
- Publication number
- MX2018002237A MX2018002237A MX2018002237A MX2018002237A MX2018002237A MX 2018002237 A MX2018002237 A MX 2018002237A MX 2018002237 A MX2018002237 A MX 2018002237A MX 2018002237 A MX2018002237 A MX 2018002237A MX 2018002237 A MX2018002237 A MX 2018002237A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- inhibitors
- gene
- treatment
- pi3k pathway
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000101 novel biomarker Substances 0.000 title 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 abstract 4
- 108091007960 PI3Ks Proteins 0.000 abstract 4
- 230000037361 pathway Effects 0.000 abstract 4
- 238000011282 treatment Methods 0.000 abstract 4
- 239000003112 inhibitor Substances 0.000 abstract 3
- 238000011144 upstream manufacturing Methods 0.000 abstract 3
- 239000000090 biomarker Substances 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 101100077748 Homo sapiens MAP2K4 gene Proteins 0.000 abstract 1
- 101150079589 MAP2K4 gene Proteins 0.000 abstract 1
- 101150086759 MAP3K1 gene Proteins 0.000 abstract 1
- 101150063858 Pik3ca gene Proteins 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000003197 protein kinase B inhibitor Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Se describen biomarcadores para el tratamiento de afecciones patológicas asociadas con la vía de PI3K tales como el cáncer y métodos para utilizar inhibidores de componentes anteriores de la vía de PI3K tales como los inhibidores de PI3K-a o inhibidores de AKT. En particular, se describen biomarcadores para la selección de pacientes en el tratamiento del cáncer, así como métodos de tratamiento terapéutico, kits diagnósticos y métodos de detección, donde los tipos de cáncer que poseen una mutación en un componente anterior de la vía de PI3K (tal como el gen PIK3CA y/o el gen AKT) y un gen MAP3K1 y un gen MAP2K4 naturales tienen más probabilidad de responder favorablemente al tratamiento con inhibidores de los componentes anteriores de la vía de PI3K.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562219698P | 2015-09-17 | 2015-09-17 | |
| PCT/EP2016/072069 WO2017046394A1 (en) | 2015-09-17 | 2016-09-16 | Novel biomarkers and methods of treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018002237A true MX2018002237A (es) | 2018-03-23 |
Family
ID=57068049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018002237A MX2018002237A (es) | 2015-09-17 | 2016-09-16 | Nuevos biomarcadores y metodos para tratar el cancer. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11685953B2 (es) |
| EP (1) | EP3350346B1 (es) |
| JP (1) | JP2018531223A (es) |
| KR (1) | KR20180049093A (es) |
| CN (1) | CN108026587A (es) |
| AU (1) | AU2016325030A1 (es) |
| BR (1) | BR112018004207A2 (es) |
| CA (1) | CA2997206A1 (es) |
| EA (1) | EA201890649A1 (es) |
| ES (1) | ES2939809T3 (es) |
| HK (1) | HK1251927A1 (es) |
| IL (1) | IL257836A (es) |
| MX (1) | MX2018002237A (es) |
| TW (1) | TW201726140A (es) |
| WO (1) | WO2017046394A1 (es) |
| ZA (1) | ZA201802481B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020041684A1 (en) * | 2018-08-23 | 2020-02-27 | Memorial Sloan-Kettering Cancer Center | Biomarkers for determining responsiveness of a cancer to pi3k inhibitors |
| CN111304326B (zh) * | 2020-02-22 | 2021-03-23 | 四川省人民医院 | 检测及靶向lncRNA生物标志物的试剂及其在肝细胞癌中的应用 |
| CN111334580A (zh) * | 2020-04-16 | 2020-06-26 | 中山大学达安基因股份有限公司 | Pik3ca基因突变检测试剂盒 |
| CN113151472A (zh) * | 2021-04-28 | 2021-07-23 | 北华大学 | 胃癌诊断标志物及其应用 |
| CN114470152B (zh) * | 2022-02-21 | 2022-09-02 | 黑龙江中医药大学 | 基于srebp-1/pi3k/akt信号通路调控乳腺癌增殖迁移的抑制剂及其应用 |
| CN114525344A (zh) * | 2022-04-22 | 2022-05-24 | 普瑞基准科技（北京）有限公司 | 一种用于检测或辅助检测肿瘤相关基因变异的试剂盒及其应用 |
| IL304567B2 (en) * | 2023-07-18 | 2024-07-01 | Oncodecipher Ltd | A method for detecting oncogenic PIK3CA |
| WO2025110738A1 (ko) * | 2023-11-24 | 2025-05-30 | 주식회사 캐니캐티케어 | 반려동물의 pik3ca 유전자 돌연변이성 종양 검출용 조성물 및 이를 이용한 반려동물의 pik3ca 유전자 돌연변이성 종양 진단방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| KR101438245B1 (ko) | 2006-08-23 | 2014-09-04 | 쿠도스 파마슈티칼스 리미티드 | Ｍｔｏｒ 억제제로서의 2-메틸모르폴린 피리도-, 피라조- 및 피리미도-피리미딘 유도체 |
| PT2201012E (pt) | 2007-10-11 | 2014-09-04 | Astrazeneca Ab | Derivados de pirrolo[2,3-d]piridina como inibidores da proteína quinase b |
| CN101939319A (zh) | 2007-12-20 | 2011-01-05 | 诺瓦提斯公司 | 联噻唑衍生物、它们的制备方法以及它们作为药物的用途 |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
| EP2640367A2 (en) | 2010-11-15 | 2013-09-25 | Exelixis, Inc. | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture |
| EP2780469A1 (en) * | 2011-11-18 | 2014-09-24 | Vanderbilt University | Markers of triple-negative breast cancer and uses thereof |
| US8892132B2 (en) * | 2012-09-05 | 2014-11-18 | Motorola Solutions, Inc. | Analytic and tracking systems and methods using over-the-air identifiers of mobile devices |
| CA2893745A1 (en) | 2012-12-04 | 2014-06-12 | Caris Mpi, Inc. | Molecular profiling for cancer |
| ES2608395T3 (es) * | 2013-01-23 | 2017-04-10 | Astrazeneca Ab | Compuestos químicos |
-
2016
- 2016-09-14 TW TW105130060A patent/TW201726140A/zh unknown
- 2016-09-16 US US15/760,858 patent/US11685953B2/en active Active
- 2016-09-16 CA CA2997206A patent/CA2997206A1/en not_active Abandoned
- 2016-09-16 ES ES16775507T patent/ES2939809T3/es active Active
- 2016-09-16 MX MX2018002237A patent/MX2018002237A/es unknown
- 2016-09-16 WO PCT/EP2016/072069 patent/WO2017046394A1/en not_active Ceased
- 2016-09-16 KR KR1020187010453A patent/KR20180049093A/ko not_active Withdrawn
- 2016-09-16 CN CN201680051358.4A patent/CN108026587A/zh active Pending
- 2016-09-16 EA EA201890649A patent/EA201890649A1/ru unknown
- 2016-09-16 JP JP2018513288A patent/JP2018531223A/ja active Pending
- 2016-09-16 BR BR112018004207A patent/BR112018004207A2/pt not_active Application Discontinuation
- 2016-09-16 AU AU2016325030A patent/AU2016325030A1/en not_active Abandoned
- 2016-09-16 HK HK18111255.7A patent/HK1251927A1/zh unknown
- 2016-09-16 EP EP16775507.3A patent/EP3350346B1/en active Active
-
2018
- 2018-03-04 IL IL257836A patent/IL257836A/en unknown
- 2018-04-16 ZA ZA2018/02481A patent/ZA201802481B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL257836A (en) | 2018-04-30 |
| EP3350346A1 (en) | 2018-07-25 |
| EP3350346B1 (en) | 2023-01-04 |
| BR112018004207A2 (pt) | 2018-09-25 |
| CN108026587A (zh) | 2018-05-11 |
| US11685953B2 (en) | 2023-06-27 |
| TW201726140A (zh) | 2017-08-01 |
| CA2997206A1 (en) | 2017-03-23 |
| ES2939809T3 (es) | 2023-04-27 |
| AU2016325030A1 (en) | 2018-05-10 |
| US20210130901A1 (en) | 2021-05-06 |
| ZA201802481B (en) | 2019-01-30 |
| HK1251927A1 (zh) | 2019-05-03 |
| KR20180049093A (ko) | 2018-05-10 |
| WO2017046394A1 (en) | 2017-03-23 |
| EA201890649A1 (ru) | 2018-08-31 |
| JP2018531223A (ja) | 2018-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018002237A (es) | Nuevos biomarcadores y metodos para tratar el cancer. | |
| EP4356960A3 (en) | Biomarkers and methods of treating pd-1 and pd-l1 related conditions | |
| MX2022005473A (es) | Metodos y composiciones para tratar canceres resistentes al inhibidor de la via de cinasas proteicas activadas por mitogeno (mapk), no cinasas extracelulares de se?al regulada (erk). | |
| WO2016109546A3 (en) | Methods and compositions for prognosis and treatment of cancers | |
| WO2015172085A3 (en) | Biomarkers for response to pi3k inhibitors | |
| AU2016246521A8 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| MA39776A (fr) | Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf | |
| EP4458849A3 (en) | Biomarkers for pancreatic cancer | |
| WO2014205266A3 (en) | Compositions and methods for detecting and treating glioblastoma | |
| MX359656B (es) | Derivados de oxoquinazolinil-butanamida. | |
| EP3686290A3 (en) | Method and kits for identifying of cdk9 inhibitors for the treatment of cancer | |
| WO2014144777A3 (en) | Lipids that increase insulin sensitivity and methods of using the same | |
| MX2016015163A (es) | Biomarcadores mit y metodos para su uso. | |
| EP4086250A3 (en) | Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same | |
| HK1251171A1 (zh) | 肿瘤生物标志物及其应用 | |
| MX364859B (es) | Derivados de imidazopirazinona. | |
| WO2013169771A3 (en) | Methods and compositions for the prognosis and treatment of relapsed leukemia | |
| WO2013081645A3 (en) | Erbb3 mutations in cancer | |
| PH12021550035A1 (en) | Combination therapy | |
| MX2016004212A (es) | Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas. | |
| AU2018244925A1 (en) | Compositions for the treatment of drug-resistant tumors and methods of use thereof | |
| MX369175B (es) | Métodos para detectar mutantes de akt resistentes a fármacos. | |
| EP3591050A3 (en) | Use of rhoa in cancer diagnosis and inhibitor screening | |
| WO2013132354A3 (en) | Gene signatures associated with efficacy of postmastectomy radiotherapy in breast cancer | |
| EP4250299A3 (en) | Genes and gene signatures for diagnosis and treatment of melanoma |